Acute oliguria

New England Journal of Medicine

Volumn 338, Issue 10, 1998, Pages 671-675

  Klahr, Saulo ^a,b   Miller, Steven B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANARITIDE; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; THIAZIDE DIURETIC AGENT;

ACUTE KIDNEY FAILURE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIALYSIS; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; OLIGURIA; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; URINALYSIS;

HUMANS; KIDNEY FAILURE, ACUTE; OLIGURIA; RISK FACTORS;

EID: 0032485437     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803053381007     Document Type: Review

References (37)

1. Levinsky NG, Bernard DB. Mannitol and loop diuretics in acute renal failure. In: Brenner BM, Lazarus JM, ed. Acute renal failure. 2nd ed. New York: Churchill Livingstone, 1988:841-56,
2. Harrington JT, Cohen JJ. Acute oliguria. N Engl J Med 1975;292:89-91.
3. Thadhani R, Pascual M, Bonvemre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
4. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993;306:481-3.
5. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-8.
6. Elasy TA, Andersen RJ. Changing demography of acute renal failure. Semin Dial 1996;9:438-43.
7. Wardle EN. Acute renal failure and multiorgan failure. Nephron 1994;66:380-5.
8. Gumming AD. Sepsis and acute renal failure. Ren Fail 1994;16:169-78.
9. Edelstein CL, Ling H, Schrier RW. The nature of renal cell injury. Kidney Int 1997;51:1341-51.
10. Klahr S. Urinary tract obstruction. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 6th ed, Boston; Little, Brown, 1997:709-38.
11. Anderson RJ, Schrier RW, Acute renal failure. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 6th ed. Boston: Little, Brown, 1997:1069-113.
12. Paller MS. Pathophysiology of acute renal failure. In: Greenberg A, ed. Primer on kidney diseases. San Diego, Calif.: Academic Press, 1994:126-33.
13. Miller SB. Renal diseases. In: Ewald GA, McKenzie CR, eds. Manual of medical therapeutics. 28th ed. Boston: Little, Brown, 1995:262-78.
14. Solomon R, Werner C, Mann D, D'Elia J, Silva P Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
15. Clark BA, Kim D, Epstein FH. Eudothelin and arrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis 1997;30:82-6.
16. Finn WF. Recovery from acute renal failure, In: Lazarus JM, Brenner BM, eds. Acute renal failure. 3rd ed. New York: Churchill Livingstone, 1993:553-96.
17. Hamel MB, Phillip RS, Davis RB, et al. Outcomes and cost effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. Ann Intern Med 1997;127:195-202.
18. Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995;26:565-76.
19. Alkhunaizi AM, Schrier RW. Management of acute renal failure: new perspectives. Am J Kidney Dis 1996;28:315-28.
20. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. N Engl J Med 1997;336:828-34.
21. Majumdar S, Kjellstrand CM. Why do we use diuretics in acute renal failure? Semin Dial 1996;9:454-9.
22. Demon MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
23. Davidman M, Olson P, Kohen J, Leither T, Kjellstrand C. Iatrogenic renal disease. Arch Intern Med 1991;151:1809-12.
24. Flancbaum L, Choban PS, Dasta JF. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med 1994;22:61-8.
25. DuBose TD Jr, Warnock DG, Mehta RL, et al. Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 1997;29:793-9.
26. Mehta RL. Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin Nephrol 1994;14:64-82.
27. Yagi N, Paganini EP. Acute dialysis and continuous renal re placement: the emergence of new technology involving the nephrologist in the intensive care setting. Semin Nephrol 1997;17;306-20.
28. Hakim RM, Wingord RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994;331:1338-42.
29. Himmelfarb J, Tolkoff-Rubin N, Chandran P, Parker RA, Wingard RL, Hakim RM. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998;9:257-66.
30. Kopple JD. Nutritional management of acute renal failure. In: Kopple JD, Massry SG, eds. Nutritional management of renal disease. Baltimore; Williams & Wilkins, 1997:713-53.
31. Feinstein EI, Blumenkrantz MJ, Healy M, et al. Clinical and metabolic responses to parenteral nutrition in acute renal failure: a controlled double-blind study, Medicine (Baltimore) 1981;60:124-37.
32. Feinstein EI, Kopple JD, Silberman H, Massry SG. Total parenteral nutrition with high or low nitrogen intakes in patients with acute renal failure. Kidney Int Suppl 1983;16:S319-S323.
33. Bywaters EGL, Beall D. Crush injuries with impairment of renal function, BMJ 1941;l:427-32,
34. Noiri E, Romanov V, Forest T, et al. Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Kidney Int 1995;48:1375-85.
35. Romanov V, Noiri E, Czerwinski F, Finsinger D, Kessler H, Goligorsky MS. Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidney, Kidney Int 1997;52:93-102.
36. Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller SB. Insulin-like growth factor I preserves renal function postoperatively, Am J Physiol 1997;272:F257-F259.
37. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993;55:766-72.